RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA
Clinical trials for RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to stop relapsed leukemia in kids and young adults
Disease control Recruiting nowThis study tests whether adding nivolumab to blinatumomab helps children and young adults (ages 1 to 30) with B-cell acute lymphoblastic leukemia that has returned after initial treatment. Participants receive either blinatumomab alone or with nivolumab. The goal is to see if the…
Matched conditions: RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:26 UTC
-
Engineered immune cells target tough childhood leukemia
Disease control Recruiting nowThis early-phase study tests a new type of cell therapy (CAR T cells) that targets two markers on leukemia cells (CD19 and CD22) in children and young adults up to age 21 whose leukemia has returned or not responded to standard treatments. The main goal is to find a safe dose and…
Matched conditions: RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated May 17, 2026 02:25 UTC
-
New hope for kids with tough leukemia: targeted therapy shows promise
Disease control Recruiting nowThis study tests a drug called inotuzumab ozogamicin in children and young adults (ages 1 to 21) whose B-cell acute lymphoblastic leukemia (B-ALL) has come back or stopped responding to treatment. The drug works like a smart bomb, attaching to a marker on leukemia cells and deliv…
Matched conditions: RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated May 13, 2026 16:04 UTC
-
New hope for tough leukemia: Triple-Drug combo trial opens
Disease control Recruiting nowThis early-phase trial tests a combination of three drugs (asparaginase, venetoclax, and blinatumomab) in adults aged 12-55 whose B-cell acute lymphoblastic leukemia has returned or not responded to prior treatment. The goal is to find a safe dose and see if the combo can help th…
Matched conditions: RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
New combo therapy offers hope for Hard-to-Treat leukemia
Disease control Recruiting nowThis study combines a targeted antibody-drug (inotuzumab ozogamicin) with low-intensity chemotherapy to treat acute lymphoblastic leukemia (ALL). It includes older adults (60+) with newly diagnosed ALL and younger adults (18-59) who are not fit for standard chemo, as well as pati…
Matched conditions: RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 06, 2026 16:13 UTC
-
New Two-Pronged attack tested for tough blood cancer in older adults
Disease control Recruiting nowThis study is testing a combination of two targeted drugs, inotuzumab ozogamicin and blinatumomab, for adults with a specific type of acute lymphoblastic leukemia (ALL). It is for older adults newly diagnosed with this cancer or adults whose cancer has come back or hasn't respond…
Matched conditions: RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 07, 2026 14:36 UTC